创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

DIAO Yuwei, LIANG Yi. Management of Cell Therapy Products in Japan and Its Implications for China[J]. Progress in Pharmaceutical Sciences, 2019, 43(12): 908-913.
Citation: DIAO Yuwei, LIANG Yi. Management of Cell Therapy Products in Japan and Its Implications for China[J]. Progress in Pharmaceutical Sciences, 2019, 43(12): 908-913.

Management of Cell Therapy Products in Japan and Its Implications for China

  • As a new breakthrough treatment, cell therapy has revolutionary significance to the treatment of refractory diseases such as cancer, and has become one of the most potential therapeutic approaches. For many years, Japan has maintained its global leadership in technology development and regulatory policies for cell therapy products, due to its complete legal system and special approval policies. This paper provides a reference for the establishment of safe, standard, stable and traceable management based on a systematic comparison of the laws and regulations over the management of cell therapy products between China and Japan.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return